• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 30th June 2022

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

OHE and Vifor Pharma present a poster at the last European Conference on Rare Diseases (ECRD) on the Mechanism of Coordinated Access to orphan medicinal products (MoCA) where evidence on avacopan for ANCA-associated vasculitis (AAV) was discussed using the Transparent…

Gayathri-2-scaled-1
Gayathri Kumar
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
PatientPayer_Adobe_missizio01-scaled-1

OHE and Vifor Pharma present a poster at the last European Conference on Rare Diseases (ECRD) on the Mechanism of Coordinated Access to orphan medicinal products (MoCA) where evidence on avacopan for ANCA-associated vasculitis (AAV) was discussed using the Transparent Value Framework.

The Office of Health Economics in collaboration with Vifor Pharma is presenting a poster on a pilot with the Mechanism of Coordinated Access to orphan medicinal products (MoCA) for avacopan in ANCA-associated vasculitis (AAV) at the European Conference on Rare Diseases (ECRD).

MoCA is a voluntary, non-binding, free-of-charge collaboration among stakeholders, created under the European Commission Process on Corporate Responsibility in the Field of Pharmaceuticals. The process provides patients, payers and companies with the opportunity for early dialogue; to discuss unmet needs of the disease, and the value that a novel treatment could bring to patients and healthcare systems.

As part of MoCA, the Transparent Value Framework (TVF) was created to structure a discussion about the value of new orphan drugs, prior to national pricing and reimbursement submissions. The framework includes four criteria: unmet need, relative effectiveness, response rate and degree of certainty, using a categorical scale with three levels (‘low’, ‘medium’, and ‘high’) to score the product under discussion, as showed below.

Figure 1: TVF criteria. Source: WG MoCA-OMP Transparent Value Framework.pdf (org.s3.amazonaws.com)

OHE supported Vifor Pharma in a pilot for their medicine avacopan in ANCA-associated vasculitis (AAV). This involved three meetings with payer representatives from 8 EU countries as well as EURORDIS and representatives from the patient group Vasculitis International. The meetings provided stakeholders with the opportunity to discuss:

  • the disease area and clinical trial program for avacopan,
  • an adaptation of the TVF disaggregating the relative effectiveness criterion into subcategories, and suggested outcomes to show the degree to which the criteria were met by avacopan, and
  • suggested scoring using the pre-agreed TVF criteria and the outcomes of avacopan clinical trials.

OHE supported Vifor Pharma in adapting the TVF by disaggregating the relative effectiveness criterion into subcategories, identifying outcomes for each criterion, and suggest the scoring using the pre-agreed TVF criteria and outcomes of avacopan clinical trials.

Suggestions for how to further improve the MoCA process include:

  • further definition of TVF methods to refine the measurement and scoring of its criteria;
  • ensuring a broader and consistent representation of payers from the participating countries, e.g. through publicly promoting the benefits of the process;
  • keeping the process voluntary and non-binding while providing more funding to ensure it is run effectively;
  • aligning with other pan-European regulatory and Health Technology Assessment (HTA) initiatives, such as PRIME and the Joint Clinical Assessment (JCA);
  • continuing to build Patient Groups capabilities to facilitate technical discussions on market access topics.

In conclusion, the MoCA process provides a valuable opportunity for early exchange of information and perspectives on the value of an orphan medicine while it is at the development stage. Integrating the patient perspective allows for a better understanding of the condition and unmet need by all participants. The TVF is a simple and pragmatic tool to inform discussions around the value of a novel orphan medicine.

 

Related research

Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc

Garau, M. and Devlin, N. (2017). Using MCDA as a decision aid in Health Technology Appraisal for coverage decisions: opportunities, challenges and unresolved questions. In “Multi-Criteria Decision Analysis to Support Healthcare Decisions” Marsh, K., Goetghebeur, M., Thokala, P., Baltussen, R. (Eds.). Springer book. DOI

  • Value, Affordability, and…
  • Events

Related Insights

_DSC0175
  • Insight
  • September 2023

The Economics of Health in a Shifting Climate: Insights from the 2023 Annual Lecture

Read more
sustainaibiity
  • Insight
  • July 2023

A Prescription for Green Healthcare Delivery: Insights from an Expert Sustainability Webinar

Read more
Slovak discounting_andrik-langfield-0rTCXZM7Xfo-unsplash_landscape
  • Insight
  • May 2023

Setting the Right Discount Rate for HTA in the Slovak Republic

Read more
Optimise_AdobeStock_576507456_landscape
  • Insight
  • April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!